NovoCure (NASDAQ:NVCR) Stock Price Up 6.8% – Should You Buy?

NovoCure Limited (NASDAQ:NVCR) was up 6.8% on Friday . The stock traded as high as $16.05 and last traded at $16.2460. Approximately 252,560 shares changed hands during mid-day trading, a decline of 86% from the average daily volume of 1,776,256 shares. The stock had previously closed at $15.21.

Trending Headlines about NovoCure

Here are the key news stories impacting NovoCure this week:

• Positive Sentiment: Q1 revenue beat and management raised FY‑26 sales outlook — Q1 revenue came in at about $174.1M (roughly 12.3% Y/Y growth) and NovoCure boosted its FY‑2026 revenue guidance to $690M–$710M, which sits around or above consensus and drove optimism. Novocure jumps after raising FY26 sales outlook, Q1 revenue beat
• Positive Sentiment: Market commentary highlights the stock rally tied to the revenue beat and outlook bump — several investor writeups frame the news as a catalyst for a breakout given stronger-than-expected sales trends. Why NovoCure Limited’s (NVCR) Stock Is Up 19.53%
• Neutral Sentiment: Management commentary and the earnings slide deck provide more color on demand, regional performance and product cadence; investors will watch subsequent quarterly cadence vs. the raised sales range. NVCR Q1 2026 Earnings Call Transcript
• Neutral Sentiment: Detailed Q1 snapshot coverage (transcript/summary) is available for investors wanting line‑by‑line trends by geography and product; these details will inform whether upside is sustainable. NovoCure: Q1 Earnings Snapshot
• Negative Sentiment: EPS missed and loss widened — Q1 GAAP EPS was a ($0.62) loss versus consensus around ($0.51), and profitability metrics (negative net margin, negative ROE) remain a concern. NovoCure (NVCR) Reports Q1 Loss, Beats Revenue Estimates
• Negative Sentiment: Analyst profitability outlook still negative — street models expect continued FY losses, so upside depends on whether revenue growth converts to margin improvement over time. NovoCure (NVCR) Q1 2026 Earnings Transcript

Wall Street Analyst Weigh In

Several equities research analysts have weighed in on NVCR shares. Wedbush reaffirmed a “neutral” rating and issued a $18.00 target price on shares of NovoCure in a research report on Thursday, April 16th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of NovoCure in a research report on Tuesday, April 21st. HC Wainwright increased their target price on NovoCure from $47.00 to $49.00 and gave the stock a “buy” rating in a research report on Thursday, February 26th. Finally, Evercore reaffirmed an “outperform” rating on shares of NovoCure in a research report on Friday. Four analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the stock currently has an average rating of “Hold” and a consensus target price of $26.93.

NovoCure Stock Performance

The company has a market cap of $1.90 billion, a P/E ratio of -13.49 and a beta of 0.82. The company has a 50 day moving average price of $12.11 and a 200-day moving average price of $12.45. The company has a quick ratio of 2.71, a current ratio of 2.90 and a debt-to-equity ratio of 0.70.

NovoCure (NASDAQ:NVCR) last released its quarterly earnings results on Thursday, April 30th. The medical equipment provider reported ($0.62) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.51) by ($0.11). NovoCure had a negative return on equity of 39.11% and a negative net margin of 20.79%.The business had revenue of $174.06 million during the quarter, compared to the consensus estimate of $167.77 million. During the same period in the previous year, the company posted ($0.31) EPS. The company’s revenue for the quarter was up 12.3% compared to the same quarter last year. Equities analysts expect that NovoCure Limited will post -1.51 EPS for the current fiscal year.

Insider Buying and Selling

In other news, insider Uri Weinberg sold 6,412 shares of the stock in a transaction on Wednesday, March 4th. The stock was sold at an average price of $13.31, for a total value of $85,343.72. Following the completion of the transaction, the insider owned 267,190 shares of the company’s stock, valued at approximately $3,556,298.90. This represents a 2.34% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Also, CEO Frank X. Leonard sold 5,607 shares of the stock in a transaction on Wednesday, March 4th. The stock was sold at an average price of $13.31, for a total value of $74,629.17. Following the completion of the transaction, the chief executive officer directly owned 493,793 shares of the company’s stock, valued at approximately $6,572,384.83. The trade was a 1.12% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last 90 days, insiders have sold 140,041 shares of company stock valued at $1,860,116. Company insiders own 5.52% of the company’s stock.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the company. Arizona State Retirement System lifted its holdings in NovoCure by 3.0% in the 3rd quarter. Arizona State Retirement System now owns 31,313 shares of the medical equipment provider’s stock worth $405,000 after purchasing an additional 916 shares during the last quarter. Larson Financial Group LLC lifted its holdings in NovoCure by 25.2% in the 4th quarter. Larson Financial Group LLC now owns 5,133 shares of the medical equipment provider’s stock worth $66,000 after purchasing an additional 1,033 shares during the last quarter. Alliancebernstein L.P. lifted its holdings in NovoCure by 0.8% in the 3rd quarter. Alliancebernstein L.P. now owns 137,106 shares of the medical equipment provider’s stock worth $1,771,000 after purchasing an additional 1,076 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. lifted its holdings in NovoCure by 25.9% in the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 5,442 shares of the medical equipment provider’s stock worth $70,000 after purchasing an additional 1,120 shares during the last quarter. Finally, Strs Ohio lifted its holdings in NovoCure by 2.2% in the 1st quarter. Strs Ohio now owns 59,400 shares of the medical equipment provider’s stock worth $647,000 after purchasing an additional 1,300 shares during the last quarter. Institutional investors own 84.61% of the company’s stock.

About NovoCure

NovoCure is a global oncology company pioneering Tumor Treating Fields (TTFields), a novel anti-mitotic therapy for solid tumors. The company’s non-invasive treatment platforms deliver low-intensity, alternating electric fields designed to disrupt cancer cell division. NovoCure’s approach offers an alternative modality to complement existing therapies in oncology, with a focus on hard-to-treat malignancies.

Founded in 2000 and headquartered in Haifa, Israel, NovoCure maintains a second operational center in Portsmouth, New Hampshire.